Advertisement

Topics

Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?

08:16 EDT 5 Aug 2017 | Topix

Could Mavyret deliver a big blow to Gilead Sciences' hopes for higher hepatitis C sales? Hepatitis C treatment has taken big steps forward over the past decade. Previous treatments including the side effect-causing drugs peg interferon and ribavirin have been replaced by next-generation drugs that deliver functional cure rates that are above 90% in as few as 12 weeks, and in some patients, as little as eight weeks.

Original Article: Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?

NEXT ARTICLE

More From BioPortfolio on "Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?"

Quick Search
Advertisement
 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...